IMMUTEP LIMITED — Board/Management Information 2007

Oct 15, 2007

==> picture [193 x 52] intentionally omitted <==

COMPANY ANNOUNCEMENT

Appointment of Director

ASX Release Stock Code: PRR

Tuesday 16[th] October 2007, Melbourne, Australia: Prima Biomed Ltd (“Prima Biomed”) is pleased to announce the appointment of a new non-executive director to its board, Mr Martin Rogers.

Mr Rogers, has a strong science and corporate consultancy background with his focus being on the incubation of business ideas and the establishment of both internal ventures and external partnerships, including finance concept origination for the likes of Macquarie Bank. Mr Roger’s role with Prima Biomed will be to strengthen business development, its investor relations and to assist the Company with seeking corporate opportunities.

Mr Rogers holds a bachelor of Chemical Engineering and a bachelor of Computer Science from the University of NSW.

For further information:

Company Enquiries Eugene Kopp (CEO) 03 9854 5700

About Prima Biomed Ltd

Prima Biomed (ASX: PRR) is a biotechnology company based in Melbourne, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima’s lead product, CVac™ has completed Phase IIa clinical development in Ovarian Cancer.

For further information, visit www.primabiomed.com.au

Prima BioMed Ltd , Suite 1, 1233 High St, Armadale VIC 3143 AUSTRALIA Ph: +61 (0)3 9854 5700 Fax: +61 (0)3 9822 7735 www.primabiomed.com.au

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity: Prima Biomed Limited

ABN: 90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Martin Rogers
Date of appointment	16thOctober 2007

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Nil

• See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

	Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities Nil

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) No. and class of securities to which interest relates

The CFO Solution www.thecfo.com.au

16.10.2007

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002